To investigate the effectiveness of AAV-DJ-mediated MYOC silencing in treating myocilin-associated glaucoma.
Used Tg-MYOCP370L mice as a model for myocilin-associated glaucoma.
Administered AAV-DJ for MYOC silencing.
Evaluated glaucomatous pathology
Gene therapy significantly reduced glaucomatous symptoms in the mice.
Observed improvements in eye health and function.
Abstract
AAV-DJ-mediated MYOC silencing effectively alleviated glaucomatous pathology in Tg-MYOCP370L mice, highlighting its potential as a gene therapy strategy for myocilin-associated glaucoma.